Therapeutic activity of SK&F 105685, a novel azaspirane with suppressor-cell inducing activity.
SK&F 105685, methotrexate (MTX) and chloroquine (CHL) were examined for their ability to inhibit paw inflammation in the adjuvant arthritic rat (AA) and for their ability to induce non-specific suppressor cells (SC) in the spleens of these animals. Compared to SK&F 105685 (84-90%) inhibition and MTX (91% inhibition) CHL, at the maximally tolerated dose, only inhibited paw lesions by 29%. MTX did not induce splenic SC activity and, despite the structural similarities between CHL and SK&F 105685, only the latter induced suppressor cells.
Badger
A M
AM
Department of Cellular Biochemistry, SmithKline Beecham Pharmaceuticals, King of Prussia, Pennsylvania 19406.
Swift
B A
BA
D000818:Animals; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001169:Arthritis, Experimental / Q000188:drug therapy* / Q000276:immunology; D002738:Chloroquine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D051381:Rats; D011917:Rats, Inbred Lew; D013141:Spiro Compounds / Q000627:therapeutic use*; D050378:T-Lymphocytes, Regulatory / Q000187:drug effects* / Q000276:immunology
D000894:Anti-Inflammatory Agents, Non-Steroidal; D013141:Spiro Compounds; C062162:SK&F 105685; D002738:Chloroquine; D008727:Methotrexate